3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
67
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
5
Non-metastatic Castration-resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Adenocarcinoma
3
Urogenital Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Diseases
1
Thrombocytosis
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Neoplasms
1
Interventions
padeliporfin
5
Mitomycin
3
pembrolizumab
2
alectinib
2
Standard of Care
2
Pluvicto
2
Nivolumab
2
Cisplatin
2
Abiraterone Acetate
2
valrubicin
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
gallium 68 PSMA-11
1
enzalutamide
1
enfortumab vedotin
1
darolutamide
1
cobimetinib
1
apalutamide
1
abiraterone
1
Therapeutics
1
Taxes
1
Sunitinib
1
Radiation Dose Hypofractionation
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
darolutamide
×
Genitourinary
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled